Management

An industry executive with a 37-year career in biotechnology and a proven track record of managing and developing business, executing strategic alliances, and building commercial and R&D capabilities.

He is the former President of Global Primary Care and President of Europe at Pfizer Inc with 16 years’ experience, and the former CEO of Asterias Biotherapeutics and Optimer Pharmaceuticals.

He holds an MBA degree from Wharton School of Business and an engineering degree from the National University of Mexico.

Scott Kahn is a seasoned financial leader with over thirty five years of experience in diverse organizations from Fortune 500 companies to start-ups. Prior to joining Starton Therapeutics, , Mr. Kahn served as CFO at Milestone Scientific, a publicly traded pharmaceutical manufacturer.  Before Milestone Scientific, Mr. Kahn was CFO and Vice President of Diopsys for approximately fifteen years where he was responsible for all accounting, finance, human resources and investor relations. Prior to joining Diopsys, Mr. Kahn served as CFO at Diamond Chemical Co., Inc., a privately held chemical manufacturer. Prior to becoming CFO at Diamond Chemical Co. Inc., Mr. Kahn was a Corporate Controller of Pharmaceutical Formulations, Inc., a publicly traded pharmaceutical manufacturer. Previously, Mr. Kahn held various finance, strategy and operational leadership roles. Mr. Kahn received a B.A. in Accounting from Franklin and Marshall College and an M.B.A. in International Business from Rutgers University. He is a Certified Public Accountant licensed in the State of New York and a Chartered Global Management Accountant.

Dr. Oliver’s experience spans 12 years in academia and 24 years in both the public and private sectors of the biotechnology/pharmaceutical industry and contract research organizations.

He served in numerous clinical development operations roles including Chief Operating Officer, SVP Clinical Research and Regulatory Affairs, Chief Science Officer, and Medical Officer. Throughout his career he successfully managed large cross-functional project teams with internal staff and oversaw CRO vendors. Dr. Oliver has significant FDA experience with both the Drug and Biologic divisions, having prepared more than 50 INDs and participated in seven successful NDA submissions for U.S./Global pharmaceutical companies. In his tenure with public and private biotechnology companies, he participated in several series of successful fund raisings. In addition, Dr. Oliver has served in licensing negotiations and out-licensing of several oncology assets.

Executive bringing more than 30 years of operational experience including 13 years in transdermal development and manufacturing.

Mr. Rensink is the former President and COO of Tapemark, where he led development, strategy implementation for pharmaceutical CDMO developing and manufacturing Transdermal Patches and Oral Thin Film products. Currently sits on the Board of Advisors for Hydra-Flex chemical dispensing systems. Holds a Masters in Engineering from Marquette University, BSME from University of Wisconsin and completed the GE Manufacturing Management Program.